Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
NTRB Catalyst Timeline
Dated clinical, regulatory and corporate events for Nutriband Inc.
Past FDA Catalysts and PDUFA Decisions
How NTRB actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Nutriband Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NTRB program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Goodman GeraldOfficer (Chief Financial Officer) | Option | 87,500 179,500 held | $1.93 | 06/06/2024 |
Hedge Fund 13F Activity
Hedge Funds invested in NTRB
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NTRB for Q3 2026. | ||||
Ownership Trends
NTRB Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How NTRB ranks across every disease it competes in
NTRB News
Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System
Nutriband Inc. announced it received a Notice of Allowance from the USPTO for trademarks related to its abuse-deterrent fentanyl transdermal system. The company plans to secure full trademark registration and is preparing to submit its brand name to regulatory bodies. The product could achieve significant annual sales, addressing a global need for effective pain management.
Read more →Nutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $1,753,274
Nutriband Inc. reported the exercise of 272,671 NTRBW warrants at $6.43, generating $1,753,274. The funds will be allocated to the clinical development of AVERSA Fentanyl and its NDA submission to the FDA. AVERSA Fentanyl aims to be the first opioid patch with abuse deterrent properties, potentially reaching annual sales of $80 million to $200 million.
Read more →Nutriband Files New Patent Application to Strengthen Intellectual Property Protection of Its Transdermal Abuse Deterrent Technology
Nutriband Inc. has filed a non-provisional patent application with the USPTO to enhance the intellectual property protection of its AVERSA™ transdermal abuse deterrent technology. This application covers improved formulations and methods that could extend patent protection for AVERSA™ products to 2046. The technology aims to prevent the abuse of drugs like opioids while ensuring patient access.
Read more →Nutriband Marks Five Years on Nasdaq – CEO Letter to Shareholders
Nutriband CEO Gareth Sheridan marked the company's fifth anniversary on Nasdaq, reflecting on milestones since the October 1, 2021 uplisting. AVERSA™ Fentanyl advanced toward an IND filing while 2021 warrants expired as scheduled. The company reported record revenues and secured patents in 46 countries. Nutriband now aims to file an NDA for its abuse-deterrent fentanyl patch.
Read more →Nutriband CEO Gareth Sheridan Featured in New Nick Shirley Documentary Confronting America's Opioid Crisis
Nutriband CEO Gareth Sheridan appeared in a new documentary by filmmaker Nick Shirley addressing the U.S. opioid crisis. He discussed how the company's AVERSA™ abuse-deterrent platform aims to reduce medication misuse while preserving patient access. The film highlights the complex challenges surrounding prescription drug abuse and diversion.
Read more →Nutriband Appoints Decorated Navy SEAL and Veterans Health Advocate Robert J. O'Neill to Advisory Board
Nutriband Inc. appointed Robert J. O'Neill, a decorated Navy SEAL, to its Advisory Board. O'Neill, known for his leadership and advocacy for veteran health, will support Nutriband's strategy as it advances its AVERSA Fentanyl patch. His extensive military experience and commitment to health treatments are seen as valuable assets for the company.
Read more →Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing
Nutriband Inc. announced that its outstanding warrants will expire on September 30, 2026, at 5 PM ET. The company will not extend the expiration date or reprice the warrants. Currently, there are 910,904 warrants outstanding, which could yield $5,856,112 if fully exercised at the strike price of $6.43.
Read more →Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit
Nutriband Inc. announced that CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The event will facilitate networking among biotechnology executives and investors. The company is focused on developing its AVERSA™ abuse-deterrent transdermal technology, which aims to enhance the safety of drugs like fentanyl.
Read more →Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch
Nutriband announced it received a Notice of Publication from the USPTO for trademarks related to its abuse deterrent fentanyl patch. The company plans to submit the brand name to the FDA for approval. The product, utilizing AVERSA technology, aims to prevent misuse and has significant sales potential in the US and global markets.
Read more →Nutriband CEO, Gareth Sheridan to Present at the 2026 Georgia Life Sciences Summit as Part of the CEO Spotlight
Nutriband Inc. announced that CEO Gareth Sheridan will present at the 2026 Georgia Life Sciences Summit on August 26. The event takes place August 25-26 at the Sandy Springs Performing Arts Centre in Georgia. Sheridan’s appearance is part of the CEO spotlight segment. The company develops transdermal pharmaceutical products using its AVERSA technology.
Read more →Nutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conference
Nutriband Inc. will present its expanding AI wellness product line at the ECRM conference in June 2026. The company aims to engage with major retailers, including Walmart and Walgreens, to discuss new product placements. Notable product launches include AI Performance Tape, AI Energy Patches, and AI Sleep solutions, which cater to the growing wellness market.
Read more →Nutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcast
Nutriband Inc. CEO Gareth Sheridan appeared on the Jack Neel Podcast to discuss the ongoing US fentanyl crisis and provide insights into the company's innovative AVERSA abuse-deterrent technology. This technology aims to enhance safety for patients who require potent medications while minimizing risks of abuse and misuse. The company continues to develop products utilizing this technology, presenting an opportunity for Nutriband to play a significant role in addressing opioid-related challenges. Sheridan's participation in the podcast underscores Nutriband's proactive approach to tackling drug abuse issues.
Read more →SELECTS COMMERCIAL BRAND NAME FOR ITS ABUSE DETERRENT FENTANYL PATCH
Nutriband Inc. has announced the selection of a worldwide brand name for its leading product, an abuse deterrent fentanyl transdermal system, which will be submitted to the FDA for approval. This product's innovative AVERSA technology aims to reduce the risks associated with misuse of fentanyl, addressing a significant medical need. With potential peak annual sales between $80 million and $200 million, Nutriband's initiative highlights the importance of effective branding and regulatory compliance in pharmaceutical development. The company is strategically partnering with Brand Institute to enhance its market presence and intellectual property rights.
Read more →Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica
Nutriband Inc. has announced that its line of Kinesiology Tapes has been approved for import and sale in Costa Rica by the Ministry of Health. The company will work with its exclusive distribution partner, Innomedica CCB, to begin marketing these products. This approval signifies a positive step for Nutriband as it seeks to expand its product offerings in the region, including its mosquito repellent patch line. The company is also focused on developing its AVERSA™ abuse-deterrent technology for transdermal products.
Read more →Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica
Nutriband Inc. has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for its AVERSA Fentanyl product, pending regulatory approval. Innomedica will also oversee and finance the necessary regulatory approvals for AVERSA and all sports tape products from Nutriband's subsidiary. The AVERSA technology aims to deter drug abuse and misuse through its innovative transdermal patches. This partnership marks a significant step for Nutriband in advancing its product offerings in the market.
Read more →Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points
Nutriband Inc. reported collecting $30,000 in weekly penalties from EarthVision Bio for delays in closing the Pocono Pharma sale. The company also announced the addition of two new directors to its board. Additionally, Nutriband reminded shareholders that 910,904 warrants will expire on October 1, 2026.
Read more →Nutriband CEO Publishes Letter to Shareholders
Nutriband Inc. announced it agreed to sell 90% of its Pocono subsidiary to EarthVision Bio for $5 million. The transaction adds $5 million to the company’s bottom line without diluting shareholders. CEO Gareth Sheridan also highlighted a 25% preferred stock dividend issued in July. The firm expects warrant expiration in October 2026 to reduce stock volatility.
Read more →Nutriband Inc. Signs Agreement to Sell Majority
Nutriband Inc. has signed an agreement to sell a 90% stake in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. Following the sale, Nutriband shareholders will retain a 10% stake in EarthVision Bio, which focuses on sustainable product development. The proceeds from this transaction will be utilized for further development of AVERSA Fentanyl, an innovative abuse-deterrent opioid patch. This transaction is set to close by December 31, 2025, reflecting a strategic move to bolster Nutriband's pharmaceutical portfolio.
Read more →Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio
Nutriband Inc. has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical to EarthVision Bio for $5 million. Following the transaction, Nutriband will retain a 10% stake in EarthVision Bio, which is focused on sustainable product development. The funds from this sale will be utilized to advance Nutriband's AVERSA Fentanyl project, an innovative abuse-deterrent opioid patch.
Read more →Nutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass Destruction
Nutriband Inc. has responded to the U.S. Executive Order designating illicit fentanyl as a weapon of mass destruction by emphasizing the importance of maintaining access to FDA-approved prescription fentanyl therapies for pain management. The company is developing Aversa™ Fentanyl, an abuse-deterrent transdermal patch designed to deter misuse while ensuring that patients receive necessary treatment for severe chronic pain. With the potential for significant market sales and a robust intellectual property portfolio, Nutriband aims to provide safer alternatives to existing fentanyl products.
Read more →